The growing siRNA pipeline: Data Byte

At least 37 companies are developing small interfering RNA (siRNA) therapies to treat genetic and rare diseases, with more than half moving into clinical trials. Of the products being explored by these companies, nearly 60% are preclinical, indicating a growing interest in the new modality.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has paved the way with the first four siRNA products on the market, and the company has more to come. In June, FDA accepted Alnylam’s NDA for  vutrisiran to treat hereditary transthyretin amyloidosis with polyneuropathy (ATTR-PN); its PDUFA date is April 14, 2022. ...